According to BioCryst Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -HK$9.72. In 2022 the company made an earnings per share (EPS) of -HK$10.34 a decrease over its 2021 EPS that were of -HK$8.01.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -HK$9.79 | -5.29% |
2022 | -HK$10.34 | 29.13% |
2021 | -HK$8.01 | -4.63% |
2020 | -HK$8.39 | 10.2% |
2019 | -HK$7.62 | 0% |
2018 | -HK$7.62 | 25.64% |
2017 | -HK$6.06 | 4% |
2016 | -HK$5.83 | 27.12% |
2015 | -HK$4.59 | -13.24% |
2014 | -HK$5.29 | 23.64% |
2013 | -HK$4.27 | -30.38% |
2012 | -HK$6.14 | -37.3% |
2011 | -HK$9.79 | 65.79% |
2010 | -HK$5.91 | 117.14% |
2009 | -HK$2.72 | -46.15% |
2008 | -HK$5.05 | -26.97% |
2007 | -HK$6.92 | -40.67% |
2006 | -HK$11.66 | 48.51% |
2005 | -HK$7.85 | 1% |
2004 | -HK$7.77 | 38.89% |
2003 | -HK$5.60 | -25% |
2002 | -HK$7.46 | 231.03% |
2001 | -HK$2.25 | -56.72% |
2000 | -HK$5.21 | 91.43% |
1999 | -HK$2.72 | 2.94% |
1998 | -HK$2.64 | -55.84% |
1997 | -HK$5.98 | 11.59% |
1996 | -HK$5.36 |